Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
21. |
ECCT/23/09/05 | LCCC 2236 Study LCCC 2236: Phase I study of self-administered Artesunate pessaries (vaginal inserts) for treatment of cervical precancer in HIV positive and HIV-negative women in Kenya |
Principal Investigator(s) 1. Chemtai Mungo 2. Jackton Omoto Site(s) in Kenya FACES, Lumumba Sub-county Hospital |
11-01-2024 |
View |
22. |
ECCT/23/11/02 | CROSSWALK Acute (A) A PHASE IB, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO‑OCCLUSIVE EPISODES (VOE) IN PATIENTS WITH SICKLE CELL DISEASE (SCD) |
Principal Investigator(s) 1. Fredrick Chite Asirwa Site(s) in Kenya 1. In this submission: International Cancer Institute (Uasin Gishu county) |
11-01-2024 |
View |
23. |
ECCT/23/09/02 | CROSSWALK Acute (A) A PHASE IB, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO‑OCCLUSIVE EPISODES (VOE) IN PATIENTS WITH SICKLE CELL DISEASE (SCD) |
Principal Investigator(s) 1. Doreen Terry Karimi Site(s) in Kenya Gertrudes Childrens Hospital |
07-12-2023 |
View |
24. |
ECCT/23/01/03 | PRAISE An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE) |
Principal Investigator(s) 1. Githanga Githanga Nyokabi Site(s) in Kenya 1. Gertrude\'s Children Hospital (Nairobi City county) 2. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county) 3. KEMRI/CRDR Kemri Clinical Research Annex Siaya County Referral Hospital Grounds (Siaya county) 4. Kombewa CRC (Kisumu county) |
19-06-2023 |
View |
25. |
ECCT/22/08/04 | Protocol H06_01TP A staged Phase I/II observer-blind, randomised, controlled, multi-country study to evaluate the safety, reactogenicity, and immune responses to the GVGH altSonflex1-2-3 vaccine against S. sonnei and S. flexneri, serotypes 1b, 2a, and 3a, in adults in Europe (Stage 1) followed by age de-escalation from adults to children and infants, and dose-finding in infants in Africa (Stage 2) |
Principal Investigator(s) 1. Deborah Chepngeno Langat Langat Site(s) in Kenya KEMRI WRP CRC KERICHO |
23-11-2022 |
View |
26. |
ECCT/22/09/03 | SINGLE DOSE VERSUS EXTENDED DO EFFECTIVENESS OFSINGLE-DOSE ANTIBIOTIC USE IN ELECTIVE CAESAREANSECTION IN PREVENTION OF SURGICAL SITE INFECTION AT JARAMOGI OGINGA ODINGA TEACHING AND REFERRAL HOSPITAL, KISUMU COUNTY,KENYA: A RANDOMIZED CONTROL TRIAL. |
Principal Investigator(s) 1. STEVEN ODHIAMBO JUMA Site(s) in Kenya JARAMOGI OGINGA ODINGA TEACHING AND REFERRAL HOSPITAL |
26-09-2022 |
View |
27. |
ECCT/22/04/02 | GO42144 A PHASE Ia/Ib DOSE-ESCALATION AND DOSE- EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITYOF GDC-6036 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS WITH A KRAS |
Principal Investigator(s) 1. Mansoor Noorali Saleh Site(s) in Kenya Aga Khan University, Nairobi |
19-08-2022 |
View |
28. |
ECCT/22/03/01 | The \"NOVATION-1\" Trial A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Safety and Efficacy of Aerosolized Novaferon + SOC vs. Placebo + SOC in Hospitalized Adult Patients with Moderate to Severe COVID-19 |
Principal Investigator(s) 1. Dr John Kinuthia Site(s) in Kenya 1. Center for Research in Therapeutic Sciences(CREATES) (Nairobi City county) 2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) 3. KEMRI Kericho (Kericho county) 4. KEMRI Siaya (Kisumu county) 5. Kenyatta National Hospital (Nairobi City county) |
27-05-2022 |
View |
29. |
ECCT/22/03/03 | HVTN 140/HPTN 101 A phase 1 dose-escalation clinical trial to evaluate the safety, tolerability, and pharmacokinetics of PGDM1400LS alone and in combination with VRC07-523LS and PGT121.414.LS in healthy, HIV-uninfected adult participants_HVTN 140/HPTN 101 |
Principal Investigator(s) 1. Josphat kosgei Site(s) in Kenya KEMRI WRP, KERICHO |
12-05-2022 |
View |
30. |
ECCT/20/06/05 | SEVUSMART Trial SEVUSMART TRIAL Sevuparin as a potential adjunctive therapy in children with severe malaria |
Principal Investigator(s) 1. Kathryn Maitland Maitland Site(s) in Kenya Kilifi County Hospital |
08-08-2021 |
View |